ADMA Biologics, Inc. (ADMA) Cash Flow Statement
ADMA Biologics, Inc. (ADMA) generated $136.7M of operating cash flow over the twelve months to 2026-06-30, spent $20.3M on capital expenditure and had free cash flow of $116.5M, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
ADMAADMA Biologics, Inc.Follow ADMA — free
—
Price chart with a free account
- Market cap
- 2.4B
- P/E TTM
- 15.3
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 11 Nov, in 18 days
| Line | FY2012 Dec 12 | FY2013 Dec 13 | FY2014 Dec 14 | FY2015 Dec 15 | FY2016 Dec 16 | FY2017 Dec 17 | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -6.9 | -10.9 | -14.7 | -15.4 | -18.3 | -37.3 | -62.7 | -76.2 | -102.0 | -112.4 | -59.5 | 8.8 | 118.7 | 50.4 | 136.7 | |
| Capital expenditure | 0.1 | 0.2 | 2.3 | 0.0 | 0.1 | 2.7 | 2.1 | 3.8 | 12.7 | 13.5 | 13.9 | 4.8 | 8.2 | 22.6 | -20.3 | |
| Free cash flow | -7.0 | -11.1 | -17.0 | -15.4 | -18.3 | -39.9 | -64.8 | -80.0 | -114.7 | -125.9 | -73.4 | 4.0 | 110.4 | 27.8 | 116.5 | |
| Share repurchases | 0.2 | — | — | — | — | — | — | — | — | — | — | 0.0 | 0.0 | 31.9 | — | |
| Stock-based compensation | 0.6 | 0.9 | 1.2 | 1.7 | 1.3 | 1.6 | 2.2 | 2.7 | 2.9 | 3.5 | 5.2 | 6.2 | 13.6 | 20.0 | — |
USD millions · SEC XBRL
ADMA Biologics, Inc. — questions
- What is ADMA Biologics, Inc.'s operating cash flow?
- $136.7M over the twelve months to 2026-06-30.
- How much does ADMA Biologics, Inc. spend on capital expenditure?
- $20.3M over the twelve months to 2026-06-30.
- What is ADMA Biologics, Inc.'s free cash flow?
- $116.5M over the twelve months to 2026-06-30: operating cash flow minus capital expenditure.
Every figure on this page comes from ADMA Biologics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.